1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Global Hepatitis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2020 - Industry Insights by Type, by Hepatitis B Drugs, and By Hepatitis C Drugs

The global hepatitis drugs market accounted for revenue of $23,222.1 million in 2014, and it is expected to grow with a CAGR of 29.7% during 2015 - 2020. Among the various types, the hepatitis C segment dominated the global hepatitis drugs market, with 76.1% share in 2014.

The global market of hepatitis drugs is up surging with a significant rate, due to increasing incidences of hepatitis, and increasing support from government organizations. Hepatitis is one of the leading causes of death around the world. According to the Hepatitis B Foundation, every year around 1 million deaths are recorded due to hepatitis B and its complications around the world. In the case of hepatitis C, the WHO stated that approximately 500,000 deaths are reported globally every year from hepatitis C related infections.

The increasing participation of various government organizations is leading to increasing awareness about various types of hepatitis infections and their management. Several government organizations are providing support, in form of funding and initiatives implemented by them for enhancing prevention, offering drug therapies, encouraging testing, and providing patient-centric services.

The major organizations include Centers for Disease Control and Prevention (CDC), WHO, U.S. Department of Health and Human Services (HHS), Hepatitis Foundation International, Immunization Action Coalition, and American Liver Foundation. Additionally, the growing geriatric population and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the market.

The aging population is increasing rapidly around the world. As per the United Nations Department of Economic and Social Affairs (UN-DESA) report on the global aging population, the population of people aged 60 years or above is growing with a very high rate. The number increased from a global share of 9.2% in 1990 to 11.7% in 2013, and is expected to reach 21.1% by the end of 2050.

The restraints associated with the growth of the global hepatitis drugs market include high capital expenditure and stringent regulatory requirements. The growing number of collaboration and partnerships is one of the latest trends observed in the market.

Geographically, North America is expected to maintain its dominance in the global market of hepatitis drugs during 2015 - 2020. This is due to increased awareness about various types of hepatitis infections and their management; and aging population in the region. In addition, the increasing R&D investments and improved healthcare infrastructures are also driving the growth of market in the region.

Europe is expected to witness marginal growth in the global market of hepatitis drugs in the near future. However, the Asian market of hepatitis drugs is expected to witness the highest growth globally, during the forecast period. This is mainly due to aging population, increasing prevalence of hepatitis, and improving healthcare infrastructure. According to WHO, most children (90%) are infected with the hepatitis A, before the age of 10 years in the developing countries, such as India and China, due to unhygienic practices and poor sanitary conditions.

The key companies operating in the global hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline PLC, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, and Mitsubishi Tanabe Pharma Corporation.

Table Of Contents

Global Hepatitis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2020 - Industry Insights by Type, by Hepatitis B Drugs, and By Hepatitis C Drugs
Chapter 1. Research Scope and Methodology

1.1 Market Definition

1.2 Objective

1.3 Market Scope

1.3.1 Market breakdown by segment

1.3.2 Market breakdown by geography

1.4 Research Methodology and Sources

Chapter 2. Executive Summary

2.1 Key Findings

2.2 Research Summary

Chapter 3. Market Outlook

3.1 Introduction

3.2 Global Trend in Hepatitis Drugs Market

3.2.1 Increasing number of collaborations and partnerships

3.3 Factors Driving the Growth of the Market and its Impact on Market Forecast

3.3.1 Increasing incidences of hepatitis

3.3.2 Increasing support from government organizations

3.3.3 Growing geriatric population

3.3.4 Increasing RandD investments in hepatitis research and drug discovery

3.3.5 Impact analysis of drivers on market forecast

3.4 Factors Hindering the Market and its Impact on Market Forecast

3.4.1 High capital expenditure

3.4.2 Stringent regulatory requirements

3.4.3 Impact analysis of restraints on market forecast

Chapter 4. Global Hepatitis Drugs Market Size and Forecast (2011 - 2020)

4.1 Global Hepatitis Drugs Market Breakdown by Type

4.2 Global Hepatitis Drugs Market Breakdown by Geography

Chapter 5. Global Hepatitis Drugs Market Breakdown by Type

5.1 Hepatitis C Drugs Market

5.1.1 Hepatitis C drugs market segmentation by region

5.1.2 Hepatitis C drugs market segmentation by drugs

5.2 Hepatitis B Drugs Market

5.2.1 Hepatitis B drugs market segmentation by region

5.2.2 Hepatitis B drugs market segmentation by drugs

5.3 Hepatitis A Drugs Market

5.3.1 Hepatitis A drugs market segmentation by region

Chapter 6. Global Hepatitis Drugs Market Breakdown by Geography

6.1 North America Hepatitis Drugs Market

6.1.1 North America hepatitis drugs market breakdown by type

6.1.2 North America hepatitis drugs market breakdown by country

6.2 Europe Hepatitis Drugs Market

6.2.1 Europe hepatitis drugs market breakdown by type

6.2.2 Europe hepatitis drugs market breakdown by country

6.3 Asia Hepatitis Drugs Market

6.3.1 Asia hepatitis drugs market breakdown by type

6.3.2 Asia hepatitis drugs market breakdown by country

6.4 Rest of the World Hepatitis Drugs Market

6.4.1 RoW hepatitis drugs market breakdown by type

Chapter 7. Pipeline Drugs for Hepatitis

Chapter 8. Drug Approval Process in the .S. and EU

8.1 Drug approval process in the U.S.

8.2 Drug Approval in the EU

Chapter 9. Competitive Positioning and Market Share Analysis

9.1 Porter's Five Forces of Competitive Position Analysis

9.1.1 Bargaining power of buyers

9.1.2 Bargaining power of suppliers

9.1.3 Threat of new entrants

9.1.4 Intensity of rivalry

9.1.5 Threat of substitutes

9.2 Global Hepatitis Drugs Market Share Analysis

Chapter 10. Company Profiles and Strategic Developments

10.1 Key Company Profiles

10.1.1 Gilead Sciences Inc.

10.1.1.1 Business overview

10.1.1.2 Product and service offerings

10.1.2 F. Hoffmann-La Roche Ltd

10.1.2.1 Business overview

10.1.2.2 Product and service offerings

10.1.3 Johnson and Johnson

10.1.3.1 Business overview

10.1.3.2 Product and services offerings

10.1.4 Merck and Co., Inc.

10.1.4.1 Business overview

10.1.4.2 Product and service offerings

10.1.5 GlaxoSmithKline plc

10.1.5.1 Business overview

10.1.5.2 Product and service offerings

10.1.6 AbbVie Inc.

10.1.6.1 Business overview

10.1.6.2 Product and service offerings

10.1.7 Novartis AG

10.1.7.1 Business overview

10.1.7.2 Product and service offerings

10.1.8 Bristol-Myers Squibb Company

10.1.8.1 Business overview

10.1.8.2 Product and service offerings

10.1.9 Dynavax Technologies Corporation

10.1.9.1 Business overview

10.1.9.2 Product and service offerings

10.1.10 Mitsubishi Tanabe Pharma Corporation

10.1.10.1 Business overview

10.1.10.2 Product and service offerings

10.2 Strategic Developments in the Hepatitis Drugs Market

10.2.1 Mergers and acquisitions

10.2.2 Collaborations and partnerships

10.2.3 Marketing authorization

10.2.4 Product launch

10.2.5 Application filling

10.2.6 Pipeline newscast

10.2.7 Others

Chapter 11. Appendix

11.1 List of Abbreviations

?



LIST OF TABLES

TABLE 1 SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION

TABLE 2 GLOBAL HEPATITIS DRUGS MARKET SNAPSHOT

TABLE 3 MAJOR COLLABORATION AND PARTNERSHIPS IN HEPATITIS DRUGS MARKET (2015)

TABLE 4 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 5 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 6 GLOBAL HEPATITIS DRUGS MARKET BREAKDOWN BY TYPE, $M (2015 - 2020)

TABLE 7 GLOBAL HEPATITIS DRUGS MARKET BREAKDOWN BY GEOGRAPHY, $M (2015 - 2020)

TABLE 8 GLOBAL HEPATITIS C DRUGS MARKET BREAKDOWN BY GEOGRAPHY, $M (2015 - 2020)

TABLE 9 GLOBAL HEPATITIS C DRUGS MARKET BREAKDOWN BY DRUGS, $M (2015-2020)

TABLE 10 GLOBAL HEPATITIS B DRUGS MARKET BREAKDOWN BY GEOGRAPHY, $M (2015 - 2020)

TABLE 11 GLOBAL HEPATITIS B DRUGS MARKET BREAKDOWN BY DRUGS, $M (2015 - 2020)

TABLE 12 GLOBAL HEPATITIS A DRUGS MARKET BREAKDOWN BY GEOGRAPHY, $M (2015 - 2020)

TABLE 13 NORTH AMERICA HEPATITIS DRUGS MARKET BREAKDOWN BY TYPE, $M (2015 - 2020)

TABLE 14 NORTH AMERICA HEPATITIS DRUGS MARKET BREAKDOWN BY COUNTRY, $M (2015 - 2020)

TABLE 15 EUROPE HEPATITIS DRUGS MARKET BREAKDOWN BY TYPE, $M (2015 - 2020)

TABLE 16 EUROPE HEPATITIS DRUGS MARKET BREAKDOWN BY COUNTRY, $M (2015 - 2020)

TABLE 17 ASIA HEPATITIS DRUGS MARKET BREAKDOWN BY TYPE, $M (2015 - 2020)

TABLE 18 ASIA HEPATITIS DRUGS MARKET BREAKDOWN BY COUNTRY, $M (2015 - 2020)

TABLE 19 ROW HEPATITIS DRUGS MARKET BREAKDOWN BY TYPE, $M (2015 - 2020)

TABLE 20 DRUGS UNDER DEVELOPMENT FOR CHRONIC HEPATITIS B, 2015

TABLE 21 CLINICAL TRIAL STAGES OF HEPATITIS C DRUGS, 2015

TABLE 22 GILEAD SCIENCES INC.- KEY FACTS

TABLE 23 F. HOFFMANN-LA ROCHE LTD - KEY FACTS

TABLE 24 JOHNSON and JOHNSON - KEY FACTS

TABLE 25 MERCK and CO., INC. - KEY FACTS

TABLE 26 GLAXOSMITHKLINE PLC - KEY FACTS

TABLE 27 ABBVIE INC. - KEY FACTS

TABLE 28 NOVARTIS AG - KEY FACTS

TABLE 29 BRISTOL-MYERS SQUIBB COMPANY - KEY FACTS

TABLE 30 DYNAVAX TECHNOLOGIES CORPORATION KEY FACTS

TABLE 31 MITSUBISHI TANABE PHARMA CORPORATION - KEY FACTS



LIST OF FIGURES

FIG 1 RESEARCH SCOPE FOR GLOBAL HEPATITIS DRUGS MARKET

FIG 2 RESEARCH METHODOLOGY FOR GLOBAL HEPATITIS DRUGS MARKET

FIG 3 TYPES OF HEPATITIS

FIG 4 MAJOR SYMPTOMS OF HEPATITIS

FIG 5 DIAGNOTSIC PROCEDURES FOR HEPATITIS

FIG 6 KEY DRUGS USED TO TREAT HEPATITIS B AND HEPATITIS C

FIG 7 AGING POPULATION AS A PERCENTAGE OF TOTAL POPULATION IN MAJOR COUNTRIES

FIG 8 BASIC DRUG DEVELOPMENT PROCEDURE

FIG 9 GLOBAL HEPATITIS DRUGS MARKET SIZE BY TYPE, $M (2014 - 2020)

FIG 10 GLOBAL HEPATITIS DRUGS MARKET SIZE BY GEOGRAPHY, $M (2014 - 2020)

FIG 11 GLOBAL HEPATITIS C DRUGS MARKET SIZE, $M (2014 - 2020)

FIG 12 GLOBAL HEPATITIS C DRUGS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 13 GLOBAL HEPATITIS C DRUGS MARKET SIZE BY REGION, $M (2014 - 2020)

FIG 14 GLOBAL HEPATITIS C DRUGS MARKET SIZE BY DRUGS, $M (2014 - 2020)

FIG 15 GLOBAL HEPATITIS B DRUGS MARKET SIZE, $M (2014 - 2020)

FIG 16 GLOBAL HEPATITIS B DRUGS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 17 GLOBAL HEPATITIS B DRUGS MARKET SIZE BY REGION, $M (2014 - 2020)

FIG 18 GLOBAL HEPATITIS B DRUGS MARKET SIZE BY DRUGS, $M (2014 - 2020)

FIG 19 GLOBAL HEPATITIS A DRUGS MARKET SIZE, $M (2014 - 2020)

FIG 20 GLOBAL HEPATITIS A DRUGS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 21 GLOBAL HEPATITIS A DRUGS MARKET SIZE BY REGION, $M (2014 - 2020)

FIG 22 GLOBAL HEPATITIS DRUGS MARKET SIZE, BY GEOGRAPHY

FIG 23 NORTH AMERICA HEPATITIS DRUGS MARKET SIZE, $M (2014 - 2020)

FIG 24 NORTH AMERICA HEPATITIS DRUGS MARKET SHARE, BY TYPE (2014 AND 2020)

FIG 25 NORTH AMERICA HEPATITIS DRUGS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 26 EUROPE HEPATITIS DRUGS MARKET SIZE, $M (2014 - 2020)

FIG 27 EUROPE HEPATITIS DRUGS MARKET SHARE, BY TYPE (2014 AND 2020)

FIG 28 EUROPE HEPATITIS DRUGS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 29 ASIA HEPATITIS DRUGS MARKET SIZE, $M (2014 - 2020)

FIG 30 ASIA HEPATITIS DRUGS MARKET SHARE, BY TYPE (2014 AND 2020)

FIG 31 ASIA HEPATITIS DRUGS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 32 ROW HEPATITIS DRUGS MARKET SIZE, $M (2014 - 2020)

FIG 33 ROW HEPATITIS DRUGS MARKET SHARE, BY TYPE (2014 AND 2020)

FIG 34 PORTER'S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS

FIG 35 MARKET SHARE OF KEY PLAYERS IN THE GLOBAL HEPATITIS DRUGS MARKET (2014)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017-2021 Molecular Diagnostics and NAT Market: Supplier Shares and Market Segment Forecasts by Country

2017-2021 Molecular Diagnostics and NAT Market: Supplier Shares and Market Segment Forecasts by Country

  • $ 9850
  • Industry report
  • December 2016
  • by Venture Planning Group

This report provides the following data: Geographic Coverage:-          France-          Germany-          Italy-          Japan-          Spain-          ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...

Hepatitis E Diagnostic Tests Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Hepatitis E Diagnostic Tests Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Global Hepatitis E Diagnostic Tests Market: Overview Hepatitis E is a liver disease that is enterically transmitted and is caused by hepatitis E virus (HEV). It is one of the five known human hepatitis ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.